The phase 3 MONET1 study evaluated motesanib ( a small-molecule inhibitor of vascular endothelial growth factor receptors ) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer ( NSCLC ) .